 Harpoon Therapeutics has an intriguing platform that can generate stable bispecific immunotherapies using their TriTAC technology. Their off-the-shelf T-cell engagers help T-cells eliminate solid tumors and hematologic cancers. The company has several catalysts for its pipeline of four clinical assets this year that can validate the TriTAC platform. 